Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at IMA901 vaccine and GM-CSF, with or without cyclophosphamide for advanced kidney cancer
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at a new vaccine treatment called IMA901 and the growth factor GM-CSF with or without one dose of cyclophosphamide for advanced kidney cancer.
Renal cell cancer is the most common type of kidney cancer. If it spreads to somewhere else in the body it can be difficult to treat. Doctors are always looking for new treatments, or new combinations of treatment that may work better.
IMA901 is a new vaccine treatment that is a type of
In this trial, people had IMA901 with GM-CSF. This is a growth factor that is sometimes used after chemotherapy to increase the number of white blood cells in the body. We know from research that GM-CSF may help vaccines such as IMA901 be more effective. Doctors thought that giving GM-CSF shortly before IMA901 would help the vaccine to work better.
Doctors also thought that one low dose of
In this trial, everyone had IMA901 and GM-CSF. Some people also had a single low dose of cyclophosphamide before the first IMA901 and GM-CSF injections.
The aims of this trial were to find out
- If IMA901 stopped kidney cancer growing or made it smaller
- If cyclophosphamide helped IMA901 to work better
- If IMA901 could help people live longer
- More about the side effects of IMA901
Summary of results
The trial team found that having cyclophosphamide before the vaccine helped IMA901 work better.
Of the 68 people this trial recruited, the researchers were able to look at the results of 64. Of these 64 people, 31 had a dose of cyclophosphamide before IMA901 and 33 did not.
Those who had cyclophosphamide before starting IMA901 lived longer than those who did not.
In general the people whose immune system responded to IMA901 in this trial lived longer than would be normally expected.
The most common side effects reported were
- Itching, reddening or swelling around the injection site
- A high temperature – fever
The trial team concluded that having a single dose of cyclophosphamide before IMA901 helped it to work better. They say more trials should be done to look at this further.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Professor Arnulf Stenzl
Experimental Cancer Medicine Centre (ECMC)